BAY 794980

Drug Profile

BAY 794980

Alternative Names: BAY-794980; Kogenate FS liposome; Kogenate liposomal; NecLip-rFVIII; PEGLip-formulated exogenous FVIII - Bayer/Zilip-Pharma; PEGLip-FVIII FS - Bayer/Zilip-Pharma; PEGylated octocog alfa sucrose - Bayer/Zilip-Pharma

Latest Information Update: 27 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 25 Jan 2010 Discontinued - Phase-II for Haemophilia A in USA (IV)
  • 26 May 2006 A clinical study has been added to the pharmacokinetics, adverse events, and Haematological Disorders therapeutic trials sections
  • 23 Nov 2005 Phase-II clinical trials in Haemophilia A in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top